AmacaThera
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Pain Management
AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Using a proprietary blend of known polymers, AmacaThera's clinically validated hydrogel platform is transforming drug delivery by enabling the precise, tunable, and sustained release of a wide range of therapeutics, from small molecules to biologics. Transforming from liquid to gel at body temperature, AmacaThera's hydrogel enables drugs to be delivered to and stay precisely where they are needed and released over days or weeks, depending on the specific needs of each therapeutic application. AmacaThera’s technology has been tested in a Phase 1 clinical trial and is Phase 2 ready.
Company HQ City:
Toronto
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2016
Lead Product in Development:
AMT-143 (PCRX-2002) long-acting injectable for post-operative pain relief
CEO
Mike Cooke
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
Phase 2 clinical data in 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}